Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00107913
Recruitment Status : Unknown
Verified April 2005 by Hematology and Oncology Specialists. Recruitment status was: Recruiting
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
Child, Adult, Older Adult
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Thrombocytopenia with bone marrow findings showing normal or increased numbers of megakaryocytes.
Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy and post splenectomy steroids.
Platelet count of 30,000 or less.
Performance status score of 2 or less.
Adequate organ function: *bilirubin< 2; *AST < 3 times normal; *creatinine < 2.
No prior treatment with anthracycline or chemically related drugs.
Pregnant or lactating women.
Presence of a malignancy other than basal cell carcinoma of the skin.